Taysha Gene Therapies Inc (NAS:TSHA)
$ 2.08 -0.07 (-3.26%) Market Cap: 419.88 Mil Enterprise Value: 369.69 Mil PE Ratio: 0 PB Ratio: 7.19 GF Score: 31/100

Q4 2021 Taysha Gene Therapies Inc Earnings Call Transcript

Mar 31, 2022 / 12:00PM GMT
Release Date Price: $6.52 (+6.02%)
Operator

Welcome to the Taysha Gene Therapies Fourth Quarter and Full Year 2021 Financial Results and Corporate Update. (Operator Instructions)

As a reminder, this call is being recorded today, March 31, 2022.

I will now turn the call over to Dr. Kimberly Lee, Chief Corporate Affairs Officer. Please go ahead.

Kimberly Lee
Taysha Gene Therapies, Inc. - Chief Corporate Affairs Officer

Good morning and welcome to Taysha's Fourth Quarter and Full Year 2021 Financial Results and Update Conference Call. Joining me on today's call are RA Session II, Taysha's President, Founder and CEO; Dr. Suyash Prasad, Chief Medical Officer and Head of R&D; and Kamran Alam, Chief Financial Officer.

After our formal remarks, we will conduct a question-and-answer session, and instructions will follow at that time.

Earlier today, Taysha issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2021. A copy of this press release is available on the company's website and through our SEC filings.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot